The Respiratory Syncytial Virus (RSV) Therapeutics Market Size was valued at USD 1.37 Billion in 202
The Respiratory Syncytial Virus (RSV) Therapeutics Market is growing rapidly owing to rising RSV awareness, which is a comprehensive health threat, and the creation of treatment alternative modes. Respiratory syncytial virus (RSV), is a common cause of respiratory disease, especially in infants and young children, as well as in older adults. In the US, RSV causes around 58,000–80,000 hospitalizations in children under 5 years of age and 60,000–160,000 hospitalizations in adults aged 65 years and older each year, according to the US Centers for Disease Control and Prevention (CDC).